drugset / Trial / NCT00835393

Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions

NCT00835393

Phase 1 Completed 50 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-label

Summary

The Objective of this study is to compare the relative bioavailability of pantoprazole sodium 40 mg delayed-released tablets (manufactured by TEVA Pharmaceutical Industries,Ltd. and distributed by TEVA Pharmaceuticals USA)with that of PROTONIX® 40mg delayed-released tablets (Wyeth- Ayerst) in Healthy, adult, non-smoking subjects under non- fasting conditions.

Timeline

Start
2003-12
Primary completion
2003-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pantoprazole Other / unclassified 40 mg

Indications

No indication recorded.